Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a bicyclic antidepressant. Used in the treatment of depression and attention deficit hyperactivity disorder (ADHD) in adults and children. Oral administration once daily.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data do not allow predicting the possible excretion in breast milk: while its high distribution volume would make it difficult, its low protein binding and low molecular weight would favor it.
May cause drowsiness, fatigue, irritability, and suicidal ideation. (FDA 2021)
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.